Page 446 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C3.2. KQ3 multivariable analyses (continued)
Author Factors Data source Duration Analyzed Population WW/AS Methods Results as described in paper
yr sample characteristics definitions
PMI
Wu 175 Clinical DOD CPDR 1990- 1158 No metastases No active Multivariable 1. Age at dx, per yr, HR=0.96 (CI
2004 database 2001 treatment Cox 0.95, 0.98), P<0.001
14767282 within 9 mo proportional 2. Log(PSA), per unit, HR=1.43
of dx hazard (CI, 1.28, 1.60); P<0.001
predicts 2º 3. Clinical stage:
treatment - T2 vs. T1, HR=1.32 (CI 1.04,
(RP, RT, 1.66), P=0.021
ADT) vs. - T3+T4 vs. T1, HR=1.62 (CI
staying on 0.99, 2.63) ; P=0.054
WW
NS: highest Gleason sum ; FH;
comorbidity; dead or alive
van As 172 Clinical Royal 2002- 326 recruited Localized PSA q 1 Multivariable free/total PSA ratio (P<0.001) and
2008 Marsden 2006 disease mo yr1, q 3 Cox T stage (P=0.006) were
18342430 Hospital, UK; mo yr 2, regression independent predictors of time to
pts dx’d in a then q 6 with respect radical treatment in patients on AS
number of mo; to radical
centers Bx at 18 treatment for NS: initial PSA; PSA density;
mo – 2 yr patients who Gleason; % positive core; Number
Treat if elected AS of positive cores; prostate volume
PSA
velocity >1 Median f/u of 22 mo
ng/mL/yr;
Gleason ≥
4+3 or
>50%
positive
cores

C-141